Belimumab for the management of systemic lupus erythematosus

Expert Opinion on Biological Therapy

Volumn 12, Issue 7, 2012, Pages 957-963

  Lutalo, Pamela M K ^a,b   D'Cruz, David P ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

B cell depletion; B lymphocyte stimulator; Belimumab; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE;

ABDOMINAL DISCOMFORT; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE ACTIVITY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERSENSITIVITY; MEDICAL LITERATURE; MEDLINE; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REVIEW; SCIENTIFIC LITERATURE; STANDARD; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84862176053     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.682980     Document Type: Review

References (31)

1. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998;41:1714-24
2. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-96
3. Sestak AL, Furnrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011;70(Suppl 1):i37-43
4. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009;18:1136-43
5. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus 2006;15:308-18
6. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
7. Symmons DP. Frequency of lupus in people of African origin. Lupus 1995;4:176-8
8. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007;56:1251-62
9. Manzi S. Epidemiology of systemic lupus erythematosus. Am J Manag Care 2001;7(16 Suppl):S474-9
10. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39
11. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: An update on clinical trial data. Drugs 2010;70:529-40
12. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
13. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum 2009;61:482-7
14. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76
15. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: A systematic review. Clin Rheumatol 2010;29:707-16
16. Jacobi AM, Huang W, Wang T, et al. Effect of longterm belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, double-blind placebo-controlled, doseranging study. Arthritis Rheum 2010;62(1):201-10.. References of considerable importance because they provide the Phase I, Phase II and Phase III clinical trial data for belimumab in SLE.
17. Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol 2011;32:388-94
18. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
19. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R204
20. Nestorov I, Papasouliotis O, Pena Rossi C, et al. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010;99:524-38
21. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (Arthritis Care & Research) 2009;61:1168-78.. References of considerable importance because they provide the Phase I, Phase II and Phase III clinical trial data for belimumab in SLE.
22. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (Arthritis Care & Research) 2009;61:1143-51
23. Luijten KM, Tekstra J, Bijlsma JW, et al. The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11:326-9
24. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.. References of considerable importance because they provide the Phase I, Phase II and Phase III clinical trial data for belimumab in SLE.
25. Furie R, Petri M I, Zamani O II, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.. References of considerable importance because they provide the Phase I, Phase II and Phase III clinical trial data for belimumab in SLE.
26. Merrill JT, Wallace DJ, Furie RA, et al. Five-year experience with belimumab, a BLys-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 2010;62(Suppl 10):608. References of importance because they provide 5-year experience data for belimumab after the clinical trials.
27. Chatham W, Wallace DJ, Stohl W, et al. Five-year safety and efficacy experience with belimumab, A BLys-specific inhibitor, in patients with systemic lupus erythematosus (SLE) Ann Rheum Dis. 2010;60(Suppl 10):192. References of importance because they provide 5-year experience data for belimumab after the clinical trials.
28. A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat- B)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057. Available from: Http://apps.who.int/trialsearch/trial.aspx? trialid=NCT00712933
29. A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat- B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. Available from: Http://clinicaltrials.gov/ct2/show/NCT00724867
30. A Phase II, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE). Available from: Http://clinicaltrials.gov/ct2/show/NCT00732940
31. A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-SC). Available from: Http://clinicaltrials.gov/ct2/show/NCT01484496